BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/7/2015 9:38:00 AM | Browse: 858 | Download: 654
 |
Received |
|
2014-04-18 21:02 |
|
Peer-Review Started |
|
2014-04-19 17:31 |
|
To Make the First Decision |
|
2014-07-10 17:25 |
|
Return for Revision |
|
2014-07-11 13:44 |
|
Revised |
|
2014-07-22 19:56 |
|
Second Decision |
|
2014-10-10 18:02 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2014-10-10 18:15 |
|
Articles in Press |
|
2014-10-10 18:15 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2014-10-18 04:13 |
|
Typeset the Manuscript |
|
2015-01-08 19:21 |
|
Publish the Manuscript Online |
|
2015-02-07 09:38 |
| ISSN |
2220-6124 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Li Tao Zhang and Jong Kwan Park |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Korea Health Technology R and D Project through the Korea Health Industry Development Institute |
|
| Ministry of Health and Welfare, South Korea |
HI13C0104 |
|
| Corresponding Author |
Jong Kwan Park, MD, PhD, Department of Urology, Biomedical Research Institute and Clinical Trial Center for Medical Devices of Chonbuk National University Hospital, Gungiro, deokjin-gu, Jeonju-si 516-180, Jeollabuk-do, South Korea. rain@chonbuk.ac.kr
|
| Key Words |
Phosphodiesterase type 5; Inhibitor; Lower urinary tract symptoms; Benign prostate hyperplasia; Tadalafil |
| Core Tip |
The efficacy of phosphodiesterase type 5 inhibitor (PDE5-I) in patients with lower urinary tract symptoms (LUTS) and benign prostate hyperplasia (BPH) has been evaluated and prescribed. Regardless of the significant improvement of total International Prostate Symptom Score and storage subscore, there are controversies about the urine flow rate. Also, we do not know the exact mechanism of how it works in the lower urinary tract. From the meta-analytical data, PDE5-I could be an alternative therapy for LUTS/BPH patients whether or not they have erectile dysfunction. Therefore, well designed large scale clinical trials are required to clarify the efficacy and action mechanisms of PDE5-Is in the management of LUTS/BPH.
|
| Publish Date |
2015-02-07 09:38 |
| Citation |
Zhang LT, Park JK. Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia? World J Nephrol 2015; 4(1): 138-147 |
| URL |
http://www.wjgnet.com/2220-6124/full/v4/i1/138.htm |
| DOI |
http://dx.doi.org/10.5527/wjn.v4.i1.138 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
